Zivo Bioscience, Inc. (ZIVO) stock
Close on Oct 19, 2026Market cap $25.96MP/E –Yield –
Zivo Bioscience, Inc. grew revenue 164.5% to $209.03K over the twelve months to Sep 30, 2025. At the latest close the market valued the company at $25.96M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2025
Valuation
- Market cap
- $25.96M
- P/E ratio
- –
- Price to sales
- 124.18
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $209.03K
- Net income
- -$8.49M
- EPS, diluted
- -$2.27
- Book value per share
- -$0.86
- Diluted shares
- 4M
Trading
- Previous close
- $6.50
- Open
- $6.50
- Day's range
- $6.50 – $6.80
- Volume
- 1,096
- Average volume (20 days)
- 1,432
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZIVO | S&P 500 | Difference | ZIVO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +112.5% | +0.6% | +111.9 pts | ||
| 3 months | +64.3% | +3.4% | +60.9 pts | ||
| Year to date | -21.8% | +13.3% | −35.1 pts | ||
| 1 year | -45.6% | +16.6% | −62.3 pts | ||
| 3 years | +61.9% | +86.4% | −24.5 pts | +17.4% | +23.1% |
| 5 years | -71.6% | +81.9% | −153.4 pts | -22.3% | +12.7% |
| 10 years | -79.8% | +318.9% | −398.6 pts | -14.8% | +15.4% |
Fifteen years at a glance
Fiscal years 2010 to 2024 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zivo Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- News
- News
- Update
About Zivo Bioscience
Biological Products, (No Diagnostic Substances)
Zivo Bioscience, Inc. operates as a research and development company focused on the biotechnology and agtech sectors. The company centers its operations on two core segments: therapeutics and nutrition, utilizing proprietary algal and bacterial cultures. In the biotech therapeutic segment, it develops bioactive molecules and extracts to combat animal and human health conditions, including poultry coccidiosis, avian influenza, and bovine mastitis. In the agtech nutrition segment, the company produces dried green algae powder for human consumption as a whole food product or functional dietary ingredient. Zivo targets partnerships with established animal health companies for licensing and commercialization, while distributing its nutrition products through third-party marketing and direct-to-consumer platforms.
Company profile, executives and historyZivo Bioscience stock: common questions
What is Zivo Bioscience's stock price?
ZIVO closed at $6.80 on Oct 19, 2026, up 4.62% on the day.
What is Zivo Bioscience's market cap?
Zivo Bioscience was worth $25.96M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ZIVO's P/E ratio?
Zivo Bioscience lost money over the twelve months to Sep 30, 2025 (diluted EPS -$2.27), so it has no meaningful P/E ratio.
How much revenue does Zivo Bioscience make?
Zivo Bioscience reported revenue of $209.03K for the twelve months to Sep 30, 2025, up 164.5% from a year earlier.
Does Zivo Bioscience pay a dividend?
No. Zivo Bioscience has not paid a cash dividend over the last twelve months.
How has ZIVO stock performed over the past year?
Including dividends, ZIVO returned -45.6% over the past year, against +16.6% for the S&P 500.
Who are Zivo Bioscience's competitors?
Companies most similar to Zivo Bioscience by business, industry and size include ATYR, ABPO, ARTV, PALI, VIVS.
See a number that looks wrong?